2012-02-10 04:03:59 - New Pharmaceuticals market report from Global Markets Direct: "Metastatic Pancreatic Cancer - Pipeline Review, H1 2012"

Metastatic Pancreatic Cancer - Pipeline Review, H1 2012

Summary

Global Markets Direct's, 'Metastatic Pancreatic Cancer - Pipeline Review, H1 2012', provides an overview of the Metastatic Pancreatic Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer. 'Metastatic Pancreatic Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report

Details at
- www.fastmr.com/prod/330104_metastatic_pancreatic_cancer_pipeline ..


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Metastatic Pancreatic Cancer.
* A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Metastatic Pancreatic Cancer therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metastatic Pancreatic Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer Therapeutics under Development by Companies
Metastatic Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Metastatic Pancreatic Cancer Therapeutics - Products under Development by Companies
Metastatic Pancreatic Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Pancreatic Cancer Therapeutics Development
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Eli Lilly and Company
Infinity Pharmaceuticals, Inc.
FibroGen, Inc.
Astellas Pharma Inc.
Chugai Pharmaceutical Co. Ltd
Pfizer Inc.
Celgene Corporation
Bayer AG
IMMUNOMEDICS, INC
Oncolytics Biotech Inc.
NanoCarrier Co., Ltd.
Rexahn Pharmaceuticals, Inc.
Oncoscience AG
MacroGenics, Inc.
OncoMed Pharmaceuticals, Inc.
Immutep S.A.
AB Science
Clovis Oncology, Inc.
Theradex Systems, Inc.
Metastatic Pancreatic Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMG-479 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abraxane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CP-4126 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Tarceva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMC-C225 + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Dalteparin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG 479 + Gemzar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abraxane + Gemzar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AB1010 + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabin - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=330104&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.